Ivan Chen - 30 Sep 2022 Form 4 Insider Report for PURE BIOSCIENCE, INC. (PURE)

Reporting relationship: Director
Issuer ticker: PURE
Reported as of: 30 Sep 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Oct 2022, 16:16:14 UTC
Prior SEC filing: 19 Jul 2022
Next SEC filing: 03 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Ivan Chen

Key filing fact

Ivan Chen filed Form 4 for PURE BIOSCIENCE, INC. (PURE) on 04 Oct 2022.

Key facts

This page summarizes Ivan Chen's Form 4 filing for PURE BIOSCIENCE, INC. (PURE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Oct 2022, 16:16.

Change

Previous filing in this sequence was filed on 19 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PURE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +150,000
Change %
Price: $0.000000
Shares after: 150,000
Date: 30 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.2000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024.